DTILbenzinga

Precision Biosciences Plans To Present Preclinical Data Supporting Advancement Of PBGENE-HBV Into Clinical Development, Company Says It Will Also Outline Design Of Its First-in-human Study, ELIMINATE-B In Patients With Chronic Hepatitis B

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on November 15, 2024 by benzinga

    Precision Biosciences Plans To Present Preclinical Data Supporting Advancement Of PBGENE-HBV Into Clinical Development, Company Says It Will Also Outline Design Of Its First-in-human Study, ELIMINATE-B In Patients With Chronic Hepatitis B | DTIL Stock News | Candlesense